Bespoke T-Cell Therapy

About Achelois BioPharma

Achelois BioPharma is an early-stage biotech pioneering a novel, patient-specific approach to T-cell therapy. By using a patient's own tumor cells to 'train' their T-cells, the company bypasses the lengthy process of identifying specific tumor antigens or engineering synthetic receptors. This platform has the potential to generate highly personalized, polyclonal T-cell products that may address tumor heterogeneity and immune evasion more effectively than off-the-shelf or single-target approaches. Founded in 2020 and based in San Diego, the company is positioned in the rapidly evolving field of cellular immunotherapy.

Therapeutic Areas

Other Solid Tumors (unspecified) Drugs